Media
On this page, we highlight information of particular relevance for the media, including news, events and featured information for journalists interested in the evaluation and safety monitoring of medicines in the European Union.
Romanian is available via eTranslation, the European Commission's machine translation service.
Translate to Romanian | Important information about machine translation
For more information and details relevant for media, see our News and events section.
For enquiries from media, please contact the EMA press office.
Featured information for journalists
Human medicines in 2025
In 2025, EMA recommended 104 medicines for marketing authorisation. Of these, 38 had a new active substance which had never been authorised in the European Union (EU) before.
Veterinary medicines in 2025
In 2025, EMA recommended 30 medicines for marketing authorisation. Of these, 13 had a new active substance.
EMA's 2024 annual report
EMA's 2024 annual report offers insights into key initiatives and priority areas that guided our work in 2024. Explore the interactive digital report or read the PDF version with figures and statistics on EMA's regulatory procedures and activities.
European medicines agencies network strategy to 2028
The strategy equips the European medicines regulatory network to respond to change and address challenges such as public health emergencies and threats, including antimicrobial resistance.
EMA communication activities: 2024 survey results
We asked stakeholders for feedback on our external communication activities via a bi-annual survey disseminated in May 2024. The results are available in a newly-published report. They help us to establish baselines and targets to measure progress, analyse trends and address areas for improvement.
Video: Working for every patient in Europe
Watch our short video for a quick and easy explanation of who EMA is and what it does. (video in English, with subtitles in 24 different languages).
Latest news
United for Health: EMA in WorldPride 2026
Science and health belong to everyone
ETF recommends updating COVID-19 vaccines to target XFG variant
Updated vaccines will help maintain protection against disease as virus continues to evolve
EU recommendations for 2026/2027 seasonal flu vaccine composition
Annual updates to virus strains ensure vaccines stay effective
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 19-21 May 2026
Outcomes of the Committee for Veterinary Medicinal Products (CVMP) meeting
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 May 2026
Eight new medicines recommended for approval; another 13 medicines recommended for extension of their therapeutic indications
New medicine for two types of pulmonary fibrosis
Jascayd slowed loss of lung function in patients with idiopathic or progressive pulmonary fibrosis